Patients with non-small cell lung cancer analyzed for EGFR: Adherence to guidelines, prevalence and outcome

Anticancer Research

Volumn 35, Issue 7, 2015, Pages 3979-3986

  Sandelin, Martin ^a   Berglund, Anders ^b   Sundström, Magnus ^a,c   Micke, Patrick ^a,c   Ekman, Simon ^a   Bergqvist, Michael ^d   Bergström, Stefan ^d   Koyi, Hirsh ^a,d   Brandén, Eva ^a,d   Janson, Christer ^a   Botling, Johan ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Uppsala Orebro Regional Oncologic Center   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d GÄVLE HOSPITAL   (Sweden)

Author keywords

EGFR; Mutation; Non small cell lung cancer; Outcome; Population; Prevalence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NON SMALL CELL LUNG CANCER; PATIENT COMPLIANCE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SWEDISH CITIZEN; TREATMENT OUTCOME; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84937124794     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386, 2015.
2. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA and Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19: 1734-1742, 2001.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M and Yankelewitz D: International association for the study of lung cancer/american thoracic society/european respiratory society international multi-disciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285, 2011.
4. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
5. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M and de Marinis F: Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung cancer 68: 319-331, 2010.
6. Scagliotti G V, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
7. Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, and Mok TS: Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8: 373-384, 2013.
8. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P and Govindan R: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 10: S1-S63, 2015.
9. Yu JL, Simmons C, Victor JC, Han D, Hogeveen S, Leighl N, and Verma S: Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. Oncologist 16: 1307-1315, 2011.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
11. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
12. Adis International L: Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Drugs R D 4: 243-248, 2003.
13. Blackhall F, Ranson M and Thatcher N: Where next for gefitinib in patients with lung cancer? Lancet Oncol 7: 499-507, 2006.
14. Tartarone A, Lerose R, Lazzari C, Gregorc V and Aieta M: Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Med Oncol 31: 78, 2014.
15. National guidelines for lung cancer care. Stockholm: Social styrelsen (National Board of Health, Sweden), p. 82 s., 2011.
16. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, Bauer TT and Mairinger T: The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 3: 2013.
17. Helland A, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jorgensen L, Ariansen S and Brustugun OT: EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol 6: 947-950, 2011.
18. Leary AF, Castro DG, Nicholson AG, Ashley S, Wotherspoon A, O'Brien ME and Popat S: Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer 48: 61-67, 2012.
19. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, and Spanish Lung Cancer G: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
20. Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA and Vink A: EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol 35: 189-196, 2012.
21. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC and Jen J: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 11: 2106-2110, 2005.
22. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C, Rieker RJ, Hartmann A, Ruemmele P, and Dietmaier W: EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 109: 1821-1828, 2013.
23. Skov BG, Hogdall E, Clementsen P, Krasnik M, Larsen KR, Sorensen JB, Skov T and Mellemgaard A: The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS 123(2): 108-115, 2014.
24. Gorden KJ, Mesbah P and Kolesar JM: EGFR inhibitors as firstline therapy in EGFR mutation-positive patients with NSCLC. J Oncol Pharm Pract 18: 245-249, 2012.
25. Gori B, Ricciardi S, del Signore E, Fulvi A and de Marinis F: Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 16(Suppl 2): S55-60, 2012.
26. Soria JC, Mok TS, Cappuzzo F and Janne PA: EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 38: 416-430, 2012.
27. Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T and Klughammer B: Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med 18: 1519-1539, 2014.